跳至主要内容
临床试验/NCT00363584
NCT00363584已完成3 期

A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer

University Hospital Southampton NHS Foundation Trust92 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2006年3月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
360
试验地点
92
主要终点
Survival at 2 years

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving capecitabine after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether capecitabine is more effective than observation in treating biliary tract cancer.

PURPOSE: This randomized phase III trial is studying capecitabine to see how well it works compared with observation in treating patients with biliary tract cancer.

详细描述

OBJECTIVES:

Primary

  • To determine whether adjuvant chemotherapy with capecitabine has any effect on 2-year survival compared to expectant treatment alone (observation) in patients who have undergone a macroscopically complete surgical resection of a biliary tract cancer.

Secondary

  • To compare capecitabine versus observation in terms of 5-year survival, relapse-free survival, toxicity, quality of life, and health economics.

研究设计

研究类型
Interventional
分配方式
Randomized
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Survival at 2 years

次要结局

  • Survival at 5 years
  • Relapse-free survival
  • Toxicity
  • Quality of life
  • Health economics

研究者

研究点 (92)

Loading locations...

相似试验

已完成
1 期
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic CancerPeriampullary AdenocarcinomaPancreatic Cancer
NCT00983268Vanderbilt-Ingram Cancer Center21
进行中(未招募)
3 期
Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryBreast Cancer
NCT00301925Institute of Cancer Research, United Kingdom4,400
已完成
2 期
Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or ChemoHead and Neck Cancer
NCT00258310Barbara Ann Karmanos Cancer Institute35
撤回
2 期
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck CancerRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Oropharynx
NCT00095641SWOG Cancer Research Network
已完成
2 期
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckHead and Neck CancerMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the Oral CavitySalivary Gland Squamous Cell CarcinomaStage IV Salivary Gland CancerStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Verrucous Carcinoma of the LarynxStage IV Verrucous Carcinoma of the Oral Cavity
NCT01044433Abramson Cancer Center at Penn Medicine44